Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1
6 affiliations
- 1Division of Immunology and Allergy, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
- 2Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
- 3Immunology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- 5Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA, USA
- 6Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Abstract
The transcription factor (TF) SPI1 (historically called PU.1) is a critical pioneer TF and regulator of hematopoiesis. It exerts exquisitely dose-dependent and stage-specific control over lymphoid, myeloid, and central nervous system–resident lineages. Structurally characterized by an intrinsically disordered N-terminal transactivation region and a highly conserved C-terminal DNA-binding E26 transformation–specific domain, SPI1 can operate alone as a monomer, via homodimerization, through epigenetic interactions, and in context-dependent transcriptional partnerships. While early animal models established its essentiality for leukopoiesis, modern human genomics has unveiled direct links between altered SPI1 function and disease. Heterozygous loss-of-function germline variants cause PU.1-mediated agammaglobulinemia, whereas somatic mutations and/or regulatory alterations can drive hematologic malignancies. Dysregulated SPI1 activity is also implicated in autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, and neurodegenerative disorders. This review reconciles foundational murine paradigms with emerging human translational data, highlights current therapeutic landscapes, and projects how single-cell multi-omics and advanced gene editing may shape future directions in the SPI1 biomedical field.
Related
- Emergent 3D genome reorganization and graded gene control from the stepwise assembly of transcriptional condensates
- Mapping of CELF1–RNA interactions reveals post-transcriptional control of lens development
- Enhancer control of promoter activity and variability via frequency modulation of clustered transcriptional bursts
- Mapping the Epigenetic Regulatory Landscape and Core Transcriptional Axes Across Cell Cycle Phases in Lung Cancer
- Post-Transcriptional Control of LINE-1 Retrotransposition by Cellular Host Factors in Somatic Cells
BibTeX
@article{mackie2026still,
title = {{Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1}},
author = {Joseph Mackie and Sangwan Sim and Lauren Y. Cominsky and Peter A. Nigrovic and Neil Romberg},
journal = {Journal of Human Immunity},
year = {2026},
month = nov,
doi = {10.70962/jhi.20260152},
url = {https://doi.org/10.70962/jhi.20260152},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1
AU - Joseph Mackie
AU - Sangwan Sim
AU - Lauren Y. Cominsky
AU - Peter A. Nigrovic
AU - Neil Romberg
PY - 2026
DA - 2026/11/12
JO - Journal of Human Immunity
DO - 10.70962/jhi.20260152
UR - https://doi.org/10.70962/jhi.20260152
AB - The transcription factor (TF) SPI1 (historically called PU.1) is a critical pioneer TF and regulator of hematopoiesis. It exerts exquisitely dose-dependent and stage-specific control over lymphoid, myeloid, and central nervous system–resident lineages. Structurally characterized by an intrinsically disordered N-terminal transactivation region and a highly conserved C-terminal DNA-binding E26 transformation–specific domain, SPI1 can operate alone as a monomer, via homodimerization, through epigenetic interactions, and in context-dependent transcriptional partnerships. While early animal models established its essentiality for leukopoiesis, modern human genomics has unveiled direct links between altered SPI1 function and disease. Heterozygous loss-of-function germline variants cause PU.1-mediated agammaglobulinemia, whereas somatic mutations and/or regulatory alterations can drive hematologic malignancies. Dysregulated SPI1 activity is also implicated in autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, and neurodegenerative disorders. This review reconciles foundational murine paradigms with emerging human translational data, highlights current therapeutic landscapes, and projects how single-cell multi-omics and advanced gene editing may shape future directions in the SPI1 biomedical field.
SN - 3065-8993
ER -